Spero Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Spero Therapeutics, Inc. (SPRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 89.75 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-12
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 183.49K shares, a 13205.66% increase year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-06-30 was 60.66K shares, a 163.50% increase year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-03-31 was 170.27K shares, a 745.65% increase year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 414.42K shares, a 379.94% increase from fiscal 2024.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 86.35K shares, a 92.56% decline from fiscal 2023.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 1.16M shares, a 35.99% decline from fiscal 2022.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 1.81M shares, a 433.67% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 89.75K shares 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 183.49K shares derived: sum of 2 quarters · filed 2026-03-26 | 244.15K shares derived: sum of 3 quarters · filed 2026-03-26 | 414.42K shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 183.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 244.15K shares derived: sum of 2 quarters · filed 2025-11-13 | 414.42K shares 10-Q · filed 2025-11-13 | 456.23K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 60.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 230.93K shares 10-Q · filed 2025-08-12 | 272.75K shares derived: sum of 3 quarters · filed 2025-08-12 | 274.12K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 170.27K shares 10-Q · filed 2025-05-13 | 212.08K shares derived: sum of 2 quarters · filed 2025-05-13 | 213.46K shares derived: sum of 3 quarters · filed 2025-05-13 | 236.48K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 41.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 43.19K shares derived: sum of 2 quarters · filed 2025-03-27 | 66.21K shares derived: sum of 3 quarters · filed 2025-03-27 | 86.35K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 1.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 24.40K shares derived: sum of 2 quarters · filed 2024-11-14 | 44.53K shares 10-Q · filed 2024-11-14 | 94.13K shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 23.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 43.16K shares 10-Q · filed 2024-08-05 | 92.75K shares derived: sum of 3 quarters · filed 2024-08-05 | 904.30K shares derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | 20.14K shares 10-Q · filed 2024-05-15 | 69.73K shares derived: sum of 2 quarters · filed 2024-05-15 | 881.28K shares derived: sum of 3 quarters · filed 2024-05-15 | 1.15M shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | 49.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 861.14K shares derived: sum of 2 quarters · filed 2024-03-13 | 1.13M shares derived: sum of 3 quarters · filed 2024-03-13 | 1.16M shares 10-K · filed 2024-03-13 |
| 2023-09-30 | 811.55K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 1.08M shares derived: sum of 2 quarters · filed 2023-11-13 | 1.11M shares 10-Q · filed 2023-11-13 | 1.15M shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 272.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 298.77K shares 10-Q · filed 2023-08-10 | 335.33K shares derived: sum of 3 quarters · filed 2023-08-10 | 945.46K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 26.52K shares 10-Q · filed 2023-05-11 | 63.08K shares derived: sum of 2 quarters · filed 2023-05-11 | 673.21K shares derived: sum of 3 quarters · filed 2023-05-11 | 1.79M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 36.56K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 646.69K shares derived: sum of 2 quarters · filed 2023-03-30 | 1.76M shares derived: sum of 3 quarters · filed 2023-03-30 | 1.81M shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 610.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 1.72M shares derived: sum of 2 quarters · filed 2022-11-14 | 1.78M shares 10-Q · filed 2022-11-14 | 1.81M shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 1.11M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 1.17M shares 10-Q · filed 2022-08-10 | 1.20M shares derived: sum of 3 quarters · filed 2022-08-10 | 1.28M shares derived: sum of 4 quarters · filed 2022-08-10 |
| 2022-03-31 | 50.64K shares 10-Q · filed 2022-05-16 | 85.22K shares derived: sum of 2 quarters · filed 2022-05-16 | 164.76K shares derived: sum of 3 quarters · filed 2022-05-16 | 283.24K shares derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | 34.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 114.13K shares derived: sum of 2 quarters · filed 2022-03-31 | 232.61K shares derived: sum of 3 quarters · filed 2022-03-31 | 339.55K shares 10-K · filed 2022-03-31 |
| 2021-09-30 | 79.55K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 198.03K shares derived: sum of 2 quarters · filed 2021-11-10 | 304.97K shares 10-Q · filed 2021-11-10 | 373.10K shares derived: sum of 4 quarters · filed 2021-11-10 |
| 2021-06-30 | 118.48K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 225.43K shares 10-Q · filed 2021-08-05 | 293.56K shares derived: sum of 3 quarters · filed 2021-08-05 | 320.09K shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 106.94K shares 10-Q · filed 2021-05-06 | 175.07K shares derived: sum of 2 quarters · filed 2021-05-06 | 201.61K shares derived: sum of 3 quarters · filed 2021-05-06 | 246.47K shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 68.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | 94.67K shares derived: sum of 2 quarters · filed 2021-03-11 | 139.52K shares derived: sum of 3 quarters · filed 2021-03-11 | 177.29K shares 10-K · filed 2021-03-11 |
| 2020-09-30 | 26.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 71.39K shares derived: sum of 2 quarters · filed 2020-11-05 | 109.16K shares 10-Q · filed 2020-11-05 | |
| 2020-06-30 | 44.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 82.62K shares 10-Q · filed 2020-08-06 | ||
| 2020-03-31 | 37.77K shares 10-Q · filed 2020-05-08 | |||
| 2019-12-31 | 291.51K shares 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |